<DOC>
	<DOCNO>NCT00808132</DOCNO>
	<brief_summary>The purpose research study evaluate safety effectiveness investigational drug treatment menopausal symptom protect endometrium ( uterine lining ) prevent postmenopausal osteoporosis . Subject participation last approximately 14.5 month .</brief_summary>
	<brief_title>Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Bazedoxifene</mesh_term>
	<criteria>Generally healthy , postmenopausal woman , age 40 64 seek treatment menopausal symptom At least 12 month spontaneous amenorrhea , OR 6 month spontaneous amenorrhea folliclestimulating hormone ( FSH ) level &gt; 40 mIU/mL Intact Uterus Use oral estrogen , progestin , androgen , selective estrogen receptor modulator ( SERM ) contain drug product within 8 week screen A history active presence clinically important medical disease : eg . cardiovascular disease ( stroke , heart attack ) , chronic renal liver disease , breast cancer , etc .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Postmenopausal Women</keyword>
	<keyword>Bazedoxifene/Conjugated Estrogens</keyword>
</DOC>